Evidence map›Paper›PMID 37048158›Full record

ArticleCells2023

Copy Number Variation in Inflammatory Breast Cancer.

Aditi Hazra, Andrea O'Hara, Kornelia Polyak, Faina Nakhlis, Beth T Harrison, Antonio Giordano, Beth Overmoyer, Filipa Lynce

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Aditi HazraDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0003-2563-0239
Andrea O'HaraBionano Genomics, San Diego, CA 92121, USA.
Kornelia PolyakInflammatory Breast Cancer Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Faina NakhlisInflammatory Breast Cancer Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Beth T HarrisonInflammatory Breast Cancer Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Antonio GiordanoInflammatory Breast Cancer Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Beth OvermoyerInflammatory Breast Cancer Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Filipa LynceInflammatory Breast Cancer Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Harvard University · USBrigham and Women's Hospital · USBioNano Genomics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of a unique genomic biomarker in de novo inflammatory breast cancer (IBC) may provide an insight into the biology of this aggressive disease. The goal of our study was to elucidate biomarkers associated with IBC. We examined breast biopsies collected from Dana-Farber Cancer Institute patients with IBC prior to initiating preoperative systemic treatment (30 samples were examined, of which 14 were eligible). Patients without available biopsies (

Indexed as

Inflammatory Breast NeoplasmsBiomarkers, TumorBreastDNA Copy Number VariationsHumansRNABiomarkers, TumorRNAchromosome 7p11copy number alterationscopy number variationEGFRinflammatory breast cancermulti-omicssubtypetriple-negative

Identifiers

PMID37048158
PMCPMC10093603
OpenAlexW4362620013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.